Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fecal microbiota transplant (Massachusetts General Hospital)
- Development stage
- Unknown
- Lead developer
- Massachusetts General Hospital
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Fecal microbiota transplant (FMT) is an investigational live biotherapeutic product being developed by Massachusetts General Hospital for the treatment of hepatic encephalopathy. Administered as oral capsules, the therapy consists of live bacterial communities derived from the fecal matter of healthy donors. [6] The primary mechanism of action is the restoration of a healthy gut microbiome, aiming to correct the dysbiosis commonly found in patients with cirrhosis and hepatic encephalopathy. [2, 6, 8] By introducing beneficial bacteria, such as those from the Ruminococcaceae and Bifidobacteriaceae families, FMT is intended to reduce the intestinal burden of harmful, neurotoxin-producing organisms, thereby improving cognitive function. [3, 4] The therapy is being evaluated in a Phase 2 clinical trial (NCT03420482). [2, 4, 5]
- Other names
- fecal microbiota transplant-Massachusetts General Hospital-hepatic encephalopathyFecal Microbiota Transplant for Hepatic Encephalopathy
Beyond the preview
Go deeper on fecal microbiota transplant (Massachusetts General Hospital).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fecal microbiota transplant (Massachusetts General Hospital).